- Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant periodRafael Barcena
Service of Liver Gastroenterology, Spain
J Hepatol 58:421-6. 2013..Short-term intravenous silibinin monotherapy is safe and shows a potent in vivo anti-HCV effect. We aimed at evaluating the safety and antiviral effect of prolonged intravenous silibinin, started immediately before liver transplantation...
- Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positive liversRafael Barcena
Department of Gastroenterology, Hospital Ramon y Cajal, Facultad de Medicina, Universidad de Alcala, Ctra Colmenar Km 9 1, 28034 Madrid, Spain
World J Gastroenterol 12:2070-4. 2006..To analyze whether the presence of anti-HBs in liver transplant recipients is effective in preventing HBV infection...
- Partial splenic embolization and peg-IFN plus RBV in liver transplanted patients with hepatitis C recurrence: safety, efficacy and long-term outcomeRafael Barcena
Liver Gastroenterology, Hospital Ramon y Cajal, Madrid 28034, Spain
Clin Transplant 24:366-74. 2010..There is limited information on the long-term outcome in liver transplant (LT) subjects undergoing partial splenic embolization (PSE) prior to full dose pegylated interferon/ribavirin (peg-IFN/RBV)...
- The magnitude of week 4 HCV RNA decay on pegylated interferon/ribavirin accurately predicts virological failure in patients with genotype 1Rafael Barcena
Service of Gastroenterology, Hospital Ramon y Cajal, Universidad de Alcala de Henares, Madrid, Spain
Antivir Ther 12:401-6. 2007..Current stopping rules during pegylated interferon (peg-IFN)/ribavirin (RBV) treatment rely on week 12 HCV RNA response, but earlier identification of non-responders offers clinical and economic advantages...
- Improved graft function in liver-transplanted patients after partial splenic embolization: reversal of splenic artery steal syndrome?Rafael Barcena
Services of Liver Gastroenterology, Hospital Ramon y Cajal, Madrid, Spain
Clin Transplant 20:517-23. 2006..To describe the functional effect of partial splenic embolization (PSE) in liver-transplanted (LT) patients with hypersplenism and hepatitis C virus (HCV) recurrence...
- Is liver transplantation advisable for isoniazid fulminant hepatitis in active extrapulmonary tuberculosis?Rafael Barcena
Hepato Gastroenterology Service, Ramon y Cajal Hospital, Madrid, Spain
Am J Transplant 5:2796-8. 2005..In conclusion, active extrapulmonary tuberculosis should perhaps be considered for liver transplantation when FHF develops due to anti-tuberculous drugs...
- Use of adefovir in the treatment of the chronic hepatitis B virus infection with resistance to lamivudineR Barcena Marugan
Department of Gastroenterology, Hospital Ramon y Cajal, Facultad de Medicina, Universidad de Alcala, Madrid, Spain
Transplant Proc 35:1841-3. 2003..There were no toxic side effects due to adefovir treatment. The data confirm that adefovir treatment has efficacy against HBV lamivudine-resistant forms...
- Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patientsLeonor Moreno
Department of Infectious Diseases, Hospital Ramon y Cajal, Madrid, Spain
AIDS 18:67-73. 2004..We evaluated the safety and efficacy of Pegylated interferon alpha2b (Peg-IFN) and a fixed dose of ribavirin in the treatment of chronic hepatitis C in HIV coinfection...
- HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-IFN-alpha-2b/ribavirinAna Moreno
Service of Infectious Diseases, Hospital Ramon y Cajal, Universidad de Alcala de Henares, Madrid, Spain
J Hepatol 43:783-90. 2005..Differences in HCV-RNA clearance during therapy might explain the lower efficacy of peg-IFN/RBV in HIV/HCV-coinfection. There are limited data on HCV-RNA clearance and treatment outcomes in liver transplanted (LT) patients...
- Safe use of pegylated interferon/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolizationJosé R Foruny
Department of Hepatology and Gastroenterology, Hospital Ramon y Cajal, Madrid, Spain
Eur J Gastroenterol Hepatol 17:1157-64. 2005..Thrombocytopenia precludes the use of pegylated interferon (peg-IFN) and ribavirin in cirrhotic patients with hepatitis C virus (HCV). We aimed to evaluate the role of PSE as a procedure allowing combined HCV therapy in this setting...
- Partial splenic embolization for the treatment of hypersplenism in cirrhotic HIV/HCV patients prior to pegylated interferon and ribavirinAna Moreno
Infectious Diseases, Hospital Ramon y Cajal, Madrid, Spain
Antivir Ther 9:1027-30. 2004..Although preliminary, these results suggest the potential role of PSE in HIV/HCV-cirrhotic subjects with hypersplenism as a procedure to allow the use of combined PEG-IFN and RBV...
- Syncytial giant cell hepatitis in human immunodeficiency virus-infected patients with chronic hepatitis C: 2 cases and review of the literatureAna Moreno
Service of Infectious Diseases, Hospital Ramon y Cajal, Universidad de Alcala de Henares, Madrid 28034, Spain
Hum Pathol 37:1344-9. 2006..Specific treatment with pegylated interferon and ribavirin can lead to histological resolution and biochemical improvement, even in the absence of HCV-RNA clearance...
- Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting responseConrado M Fernández-Rodríguez
Hospital Universitario Fundacion Alcorcon, Madrid, Spain
Am J Gastroenterol 105:2164-72; quiz 2173. 2010..Patients with hepatitis C virus (HCV) cirrhosis are difficult to treat and have a high risk of liver decompensation or hepatocellular carcinoma. We sought to identify factors that could predict treatment response...
- Liver transplantation in HIV-infected recipientsSantiago Moreno
Department of Infectious Diseases, Liver Transplant Unit, Hospital Ramon y Cajal, Universidad de Alcala de Henares, 28034 Madrid, Spain
Liver Transpl 11:76-81. 2005..If indicated, an antiretroviral regimen consisting of 3 nucleosides could be used to avoid interactions with immunosuppressive drugs...
- Severe rhabdomyolysis due to rosuvastatin in a liver transplant subject with human immunodeficiency virus and immunosuppressive therapy-related dyslipidemiaAna Moreno
Infectious Diseases Service, Hospital Ramon y Cajal, Madrid, Spain
Liver Transpl 17:331-3. 2011....
- Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patientsJesus Fortun
Infectious Disease Department and Liver Transplant Group, Hospital Ramon y Cajal, Crtra Colmenar Km 9 1, Madrid 28034, Spain
J Antimicrob Chemother 52:813-9. 2003..Invasive fungal infections (IFI) are associated with high mortality in liver transplant recipients. Prevention remains an elusive goal, especially for IFI caused by moulds...
- Response of TT virus to IFN plus ribavirin treatment in patients with chronic hepatitis CJavier Moreno
Department of Gastroenterology, Hospital Ramony Cajal, Ctra Colmenar, Km 9 1, 28034 Madrid, Spain
World J Gastroenterol 10:143-6. 2004..PEG-IFN plus ribavirin have been useful in the treatment of chronic hepatitis C infection. This study investigated the responses of TT virus (TTV) and hepatitis C virus (HCV) to PEG-IFN plus ribavirin therapy...
- High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirinAna Moreno
Infectious Diseases, Hospital Ramon y Cajal, Universidad de Alcala de Henares, Madrid, Spain
Antivir Ther 9:133-8. 2004..Nucleoside analogues may induce mitochondrial toxicity, particularly didanosine. Ribavirin increases didanosine exposure, which might be clinically relevant when coadministered in HIV/HCV-coinfected patients...
- False-positive results of Aspergillus galactomannan antigenemia in liver transplant recipientsJesus Fortun
Department of Infectious Diseases, Hospital Ramon y Cajal, Madrid, Spain
Transplantation 87:256-60. 2009..Aspergillus galactomannan (GM) antigenemia is an early marker of invasive aspergillosis (IA), but may yield false-positive results. A prospective study, testing GM periodically in serum samples of liver transplant recipients, was performed...
- Risk factors for invasive aspergillosis in liver transplant recipientsJesus Fortun
Infectious Diseases Department and Liver Transplant Unit, Ramon y Cajal Hospital, Alcala de Henares University, Madrid, Spain
Liver Transpl 8:1065-70. 2002..Cytomegalovirus infection and increased immunosuppression favor invasive aspergillosis during the late posttransplantation period. Aspergillus antigenemia seems to be a good predictor of invasive aspergillosis...
- [Acute hepatitis E in Madrid: description of 18 cases]Maria Luisa Mateos
Servicio de Microbiología Hospital Ramón y Cajal Madrid España
Gastroenterol Hepatol 29:397-400. 2006..However, in the last few years, several sporadic autochthonous hepatitis E cases have been reported in Europe and no risk factors, such as visiting to endemic areas, could be found in these patients...
- Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysisJosé L Calleja
Department of Gastroenterology and Hepatology, University Hospital Puerta de Hierro Majadahonda, IDIPHIM and CIBEREHD, Madrid, Spain
Liver Int 35:90-100. 2015..The addition of protease inhibitors (PIs) changed the hepatitis C virus (HCV) treatment standards and improved sustained viral response (SVR) rates in patients with genotype 1 HCV infection...